ImmuCell Corporation
ICCC
$9.92
$0.151.54%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -1.61% | -8.41% | 17.76% | 11.16% | 52.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.61% | -8.41% | 17.76% | 11.16% | 52.10% |
| Cost of Revenue | -4.14% | -29.02% | -14.51% | -5.02% | 48.57% |
| Gross Profit | 2.78% | 49.22% | 129.00% | 46.12% | 58.66% |
| SG&A Expenses | 1.32% | 20.14% | -10.72% | 11.00% | 16.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.45% | -16.71% | -14.35% | -8.04% | 27.94% |
| Operating Income | 19.41% | 103.50% | 141.08% | 472.41% | 230.41% |
| Income Before Tax | -646.64% | 80.68% | 132.92% | 431.94% | 145.73% |
| Income Tax Expenses | -45.00% | 246.15% | 46.15% | 46.15% | 361.54% |
| Earnings from Continuing Operations | -653.65% | 80.09% | 132.77% | 430.44% | 145.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -653.65% | 80.09% | 132.77% | 430.44% | 145.15% |
| EBIT | 19.41% | 103.50% | 141.08% | 472.41% | 230.41% |
| EBITDA | 11.83% | 597.80% | 272.97% | 388.45% | 552.82% |
| EPS Basic | -646.88% | 82.07% | 128.35% | 385.13% | 139.16% |
| Normalized Basic EPS | 26.30% | 90.67% | 128.36% | 303.13% | 174.04% |
| EPS Diluted | -646.88% | 77.78% | 127.80% | 366.67% | 138.40% |
| Normalized Diluted EPS | 24.38% | 90.67% | 128.36% | 303.13% | 174.04% |
| Average Basic Shares Outstanding | 1.24% | 10.80% | 15.64% | 15.87% | 15.29% |
| Average Diluted Shares Outstanding | 2.86% | 10.80% | 15.64% | 15.87% | 15.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |